Preferences for Multiple Sclerosis Treatments

Mansfield, Carol; Thomas, Nina; Gebben, David J.; Lucas, María Raquel; Hauber, A. Brett

doi:10.7224/1537-2073.2016-039

Cited by 24 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some cases, patients most valued symptom control, in other cases, patients prioritized delaying disability, and in yet other cases, patients focused on safety and avoiding AEs. Overall, patients preferred oral administration to injections, particularly frequent injections (Garcia-Dominguez et al, 2016;Lebrun et al, 2018;Mansfield et al, 2016;Poulos et al, 2016). One independent study found patients with MS placed more importance on DMT monthly out-of-pocket costs and mode of administration than AEs or efficacy (Hincapie et al, 2017).…”

Section: Tablementioning

confidence: 99%

Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS

Vermersch

Cascione

et al. 2020

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 99%

Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS

Vermersch

Cascione

et al. 2020

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…The conditional relative importance for each attribute was retrieved using the model estimates. As commonly seen in the literature [84][85][86][87] , a weight of 10 was assigned to the most important attribute, calculating the others relative to the most important attribute. Maximum acceptable risk post-hoc calculations reflect the trade-offs between specific attributes and a reduction in the risk of dying from cancer.…”

Section: Discussionmentioning

confidence: 99%

Patient Preferences in Surveillance: Findings From a Discrete Choice Experiment in the “My Follow-Up” Study

McFerran

Boeri²,

Kee

2020

Value in Health

View full text Add to dashboard Cite

Objective: Approximately 800,000 people die globally from colorectal cancer (CRC) every year. Prevention programmes promote early detection, but for people with pre-cancerous lesions, tailoring surveillance to include lifestyle-change programmes could enhance prevention potential and improve outcomes. Methods:Those with intermediate or high-risk polyps removed during CRC-screening colonoscopy within the Northern Ireland CRC Screening programme were invited to complete 8 discrete choice questions about tailored surveillance, analysed using random-parameters logit and latent class modelling approach.Results: 231 participants, (77% male) self-reported comorbid hypertension (53%), high cholesterol (48%) and mean BMI of 28.7 (overweight). Although 39% of participants were unaware of their CRC risk-status, 30.9% indicated they were already making changes to reduce their risk. Although all respondents were significantly risk and cost averse, the latent class analysis identified three segments (classes): i)Class 1 (26.8%) significantly favoured phone or email support for a lifestyle change, a 17-month testing interval, and non-invasive testing.ii) Class 2 (48.4%) preferred the status-quo.iii) Class 3 (24.7%) significantly favoured further risk reduction and invasive testing.Conclusions: This is the first documented preference study focusing on post-polypectomy surveillance offering lifestyle interventions. Although current care is strongly preferred, risk and cost aversion are important for participants. Latent class analysis shows that some respondents are willing to change diet and lifestyle behaviours, reflecting a teachable moment, with opportunities to personalise and optimise surveillance. Significant discordance between perceived and known risk of recurrence and limited recall of risk information provided within current practice suggest necessary improvements to surveillance programmes.

show abstract

“…Originally developed for consumer marketing purposes, medical researchers have used this https://doi.org/10.1017/cts.2022.372 method to analyze patient preferences in numerous disease areas including AD, multiple sclerosis, and exercise research [26][27][28] .…”

Section: Introductionmentioning

confidence: 99%

“…One approach to investigate the patient perspective is through a choice-based conjoint (CBC) experiment, a survey method designed to measure the preferences of patients and the tradeoffs they would tolerate in a treatment [25]. Originally developed for consumer marketing purposes, medical researchers have used this method to analyze patient preferences in numerous disease areas including AD, multiple sclerosis, and exercise research [26][27][28].…”

Section: Introductionmentioning

confidence: 99%

Preventive drugs for Huntington’s disease: A choice-based conjoint survey of patient preferences

Parrish

Hanson‐Kahn

Srinivasan

et al. 2022

J. Clin. Trans. Sci.

View full text Add to dashboard Cite

show abstract

Preferences for Multiple Sclerosis Treatments

Abstract: Background: The growing number of treatments for relapsing multiple sclerosis (MS) provides opportunities to consider patient preferences in treatment decisions.

Cited by 24 publications

References 25 publications

Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS

Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS

Patient Preferences in Surveillance: Findings From a Discrete Choice Experiment in the “My Follow-Up” Study

Preventive drugs for Huntington’s disease: A choice-based conjoint survey of patient preferences

Contact Info

Product

Resources

About